生长抑素受体2在小细胞肺癌中的表达及其与患者生物学特征的关系-东南大学学报医学版

生长抑素受体2在小细胞肺癌中的表达及其与患者生物学特征的关系

单位：东南大学医学院, 江苏南京 210009

分类号：R734.2

出版年·卷·期（页码）：2021·40·第一期（83-88）

摘要：

目的：检测小细胞肺癌（SCLC）标本中生长抑素受体2（SSTR2）的表达，并对SCLC患者的生物学特征（年龄、性别、吸烟、TNM分期、预后）进行统计学分析，旨在判定SSTR2的表达与患者生物学特征是否具有相关性，评估能否将SSTR2作为诊断、治疗的靶点，拓宽SCLC的治疗途径。方法：采用免疫组化方法检测SCLC组织标本、NCI-H446小细胞肺癌细胞株SSTR2的表达，并分别以非肿瘤肺组织及上皮细胞作为对照。收集SCLC患者一般资料，评估SSTR2表达与患者生物学特征的关系。结果：小细胞肺癌株NCI-H446中SSTR2呈强阳性表达（+++），主要表达于细胞膜。上皮对照细胞中，SSTR2无表达。SSTR2在SCLC组织中阳性表达率为69.6%（32/46），强阳性表达率为34.8%（16/46），中度阳性表达率为23.9%（11/46），弱阳性表达率为10.9%（5/46）。非肿瘤肺组织中阳性表达率为10%（1/10），且为弱阳性表达。SSTR2表达阳性者和阴性者的平均生存期分别为33.9个月和28.4个月（中位生存期：21个月vs 24个月），差异无统计学意义（P＝0.883）。SSTR2表达与SCLC患者的性别、年龄、是否吸烟、TNM分期以及生存期均无明显相关性（P>0.05）。结论：SSTR2在SCLC中表达率较高，其可作为生长抑素及其类似物靶向治疗SCLC的稳定靶点。而SCLC的SSTR2表达与患者的年龄、性别、吸烟史、TNM分期及生存期无明显相关性，其可能不能作为判断SCLC患者的预后指标。

Objective: To detect the expression of somatostatin receptor 2 (SSTR2) in specimens of patients with small cell lung cancer(SCLC) and to statistically analyze their biological characteristics (age, gender, smoking, TNM staging, and prognosis), in order to determine whether the expression of SSTR2 and the biological characteristics of patients has correlation, evaluate whether SSTR2 can be used as a target for diagnosis and treatment, broaden the treatment of SCLC. Methods: Using immunohistochemical method, the expression of SCLC was detected in SCLC tissue samples and small cell lung cancer cell line, then non-tumor lung tissue and epithelial cells were served as controls. General data of patients who suffer from SCLC were collected to evaluate the relationship between SSTR2 expression and biological characteristics of patients. Results: In human SCLC NCI-H446, SSTR2 was strongly positive(+++), mainly expressed in cell membrane. In epithelial control cells, no SSTR2 expressed. The positive expression rate of SSTR2 in SCLC tissues was 69.6% (32/46), strong positive expression rate being 34.8%(16/46), medium positive expression rate 23.9%(11/46), weak positive expression rate 10.9%(5/46). The positive expression rate in non-tumor lung tissue was 10% (1/10),which was weakly positive. The average survival time of SSTR2 positive and negative was 33.9 months and 28.4 months (median survival:21 months vs 24 months), P=0.883), There was no significantly statistical difference. Analysis of the correlation between SSTR2 expression and biological characteristics of patients showed that there was no significant correlation between SSTR2 expression and SCLC patient's sex, age, smoking, TNM stage and survival time (P>0.05). Conclusion: Among patients who suffer from SCLC, no significant correlation exist among the expression rate of SSTR2 and age, sex, smoking history, TNM stage and survival, which means the expression of SSTR2 may not be a prognostic factor of recognizing patients who suffer from SCLC. However, the expression rate of SSTR2 among patients who suffer from SCLC is very high, which indicates that SSTR2 can be used as a stable target for somatostatin and its analogues in the targeted therapy of SCLC.

参考文献：

[1] BYERS L A,RUDIN C M.Small cell lung cancer:where do we go from here?[J].Cancer,2015,121(5):664-672.
[2] OBERG K,HELLMAN P,KWEKKEBOOM D,et al.Neuroendocrine bronchial and thymic tumours:ESMO Clinical Pracice Gulidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2010,21(Suppl 5):v220-v222.
[3] GOVINDAN R,PAGE N,MORGENSZTEM D,et al.Changing epidemiology of small-cell lung cancer in the United States over the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J].Clin Oncol,2006,(24):4539-4544.
[4] NAVADA S,LAI P,SCHWARTZ A,et al.Temporal trends in small cell lung cancer:analysis of the national Surveilance,Epidemiology and End-Results(SEER) database[J].Clin Oncol,2006,(24):Abstract 7082-7082.
[5] BRAZEAU P,VALE W,BURGUS R,et al.Somatostatin[J].Recent ProgHorm Res,1975,31:365-397.
[6] LI M,ZHANG R,LI F,et al.Transfection of SSTR-1 and SSTR-2 inhibit its Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue[J].Am Coll Surg,2005,201(4):571-578.
[7] LI M,FISHER W E,KIM H J,et al.Somatostatin,somatostatin receptors,and pancreatic cancer[J].World J Surg,2005,29(3):293-296.
[8] FISSELER-ECKHOFF A,DEMES M,Neuroendocrine tumors of the lung[J].Cancers (Basel),2012,4(3):777-798.
[9] GUSTAFSSON B I,KIDD M,CHAN A,et al.Bronchopulmonary neuroendocrine tumors[J].Cancer,2008,113(1):5-21.
[10] LEWIN J,CULLINANE C,AKHURST T,et al.Peptide receptor chemoradionuclide therapy in small cell carcinoma:from bench to bedside[J].Eur J Nucl Med Mol Imaging,2015,42(1):25-32.
[11] TARTARONE A,LEROSE R,AIETA M.Somatostatin analog therapy in small cell lung cancer[J].Semin Nucl Med,2016,46(3):239-242.
[12] BODEI L,KWEKKEBOOM D J,KIDD M,et al.Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer[J].Semin Nucl Med,2016,46(3):225-238.
[13] SCHULZ S,PAULI S U,SCHULZ S,et al.Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A[J].Clin Cancer Res,2000,6(5):1865-1874.
[14] ERLANOLSSON A,FORSSELL-ARONSSON E,SEIDAL T,et al.Binding of TS1,an anti-keratin 8 antibody,in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment:a histological study in xenografted mice[J].EJNMMI R,2011,(1):19.
[15] 王秀问.生长抑素受体介导的靶向治疗对非小细胞肺癌耐药的逆转作用及其机制研究[D].济南:山东大学,2009.
[16] KAEMMERER D,SPECHT E,SANGER J,et al.Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms:new diagnostic,prognostic,and therapeutic markers[J].Clin Endocrinol Metab,2015,100(3):831-840.
[17] RIGHI L,VOLANTE M,TAVAGLIONE V,et al.Somatostatin receptor tissue distribution in lung neuroendocrine tumours:a clinicopathologicand immunohistochemical study of 218 ‘clinically aggressive’ cases[J].Ann Oncol,2010,21(3):548-555.
[18] 王少华,于泽平,李宁,等.原发性乳腺浸润性导管癌组织中生长抑素受体表达及其预后价值[J].医学研究生学报,2008,21(11):1172-1174.
[19] 刘卫兵,李洪光.SSTRl-3亚型蛋白在大肠癌组织中的表达及临床意义[J].现代医学,2012,12,40(6):645-648.
[20] BUSCAIL L,SAINT-LAURENT N,CHASTRE E,et al.Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer[J].Cancer Res,1996,56(8):1823-1827.
[21] WAR S A,KIM B,KUMAR U.Human somatostatin receptor-3 distinctively induces apoptosis in MCF-7 and cell cycle arrest in MDA-MB-231 breast cancer cells[J].Mol Cell Endocrinol,2015,(413):129-144.
[22] MOLLER L N,STIDSEN C E,HARTMANN B,et al.Somatostatin receptors.[J]Biochim Biophys Acta,2003,1616(1):1-84.
[23] BOUSQUET C,DELESQUE N,LOPEZ F,et al.sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1[J].Biol Chem,1998,273(12):7099-7106.
[24] LAPA C,HANSCHEID H,WILD V,et al.Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a Target for peptide receptor radionuclide therapy[J].Oncotarget,2016,7(15):20033-20040.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录